Clinical Data Management Applications & Studies
-
Electronic Columbia Suicide Severity Rating Scale Included In A Wider Range Of Clinical Studies
8/25/2017
The objective of this study was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device. The results supported the validity and reliability of the new tablet-based electronic Columbia-Suicide Severity Rating Scale and allow its inclusion in a wider range of clinical studies, particularly where a tablet is also being used to collect other study data.
-
Celgene Leverages ERT eCOA Data for FDA Approval
8/24/2017
A biopharmaceutical company wanted to determine whether patients treated with an oral inhibitor of phosphodieasterase-4 (PDE-4) would show improvement in signs and symptoms of PsA. They used ERT eCOA tablets to collect data about patient symptoms as observed by physicians through the ACR assessment which was used to assess efficacy. Results showed reduced monitoring time and costs, decreased time to database lock, and FDA approval.
-
Accelerate Your Database Lock Using Clean Patient Optics
7/17/2017
Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies. These tools can help you improve the efficiency in which you close out and lock your clinical database.
-
Clinical Trial Recruitment Managers Can Be More Efficient And Reduce Costs
9/13/2013
This case study analyzes Accel Clinical Services, its challenges associated with their CTMS system and the results achieved via the implementation of Bio-Optronics’ clinical trial management system.
-
Alnylam Puts Sites And Patients First With IQVIA Technologies Investigator Site Portal
When Alnylam Pharmaceuticals began developing medicines for rare diseases with few or no treatment options, the company’s leaders knew they needed to design clinical trials that kept patient well-being and disease burden at the forefront.